Buy Strattera

Strattera

Strattera: Atomoxetine - Neurology Medication Overview

Product name: Strattera Active ingredient: Atomoxetine Therapeutic class: Neurology - selective norepinephrine reuptake inhibitor (NRI) Formulation: Pill (capsule) - available strengths 10 mg, 18 mg, 25 mg, 40 mg Regulatory status in the UK: Prescription-only medicine (POM) authorised by the Medicines and Healthcare products Regulatory Agency (MHRA)

How Atomoxetine Works in the Body

Atomoxetine increases the concentration of norepinephrine-a neurotransmitter that regulates attention, impulse control, and activity levels-by blocking its re-uptake into nerve cells. By maintaining higher norepinephrine levels in the prefrontal cortex, the drug helps improve focus and reduce hyperactive or impulsive behaviours typical of attention-deficit/hyperactivity disorder (ADHD).

Key pharmacologic points:

• Target: Norepinephrine transporter (NET) inhibition.
• Onset: Clinical effects usually emerge within 1-2 weeks; full benefit may take up to 6-8 weeks.
• Duration: Once-daily dosing provides steady plasma concentrations for 24 hours.
• Metabolism: Primarily via hepatic CYP2D6; individuals who are poor CYP2D6 metabolizers may have higher plasma levels.

Conditions Treated with Strattera

Strattera is approved in the United Kingdom for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents, and adults. It is indicated when a non-stimulant option is preferred or when stimulant therapy is contraindicated or not tolerated.

• Primary indication: Management of ADHD symptoms- inattention, hyperactivity, and impulsivity.
• Target populations:
• Children (≥6 years) and adolescents, dose adjusted to body weight.
• Adults, dose adjusted to clinical response and tolerability.

Evidence-Based Off-Label Uses

Some clinical studies have explored atomoxetine for other conditions, but these uses are not approved by the MHRA and should only be considered under specialist supervision.

• Generalised Anxiety Disorder (GAD): Small-scale trials suggest modest benefit, particularly when anxiety co-exists with ADHD.
• Autistic Spectrum Disorder (ASD) with hyperactivity: Limited evidence indicates possible reduction of irritability and hyperactivity.

Disclaimer: Off-label use requires careful risk-benefit assessment by a qualified healthcare professional.

Who Should (Not) Use Strattera?

Ideal candidates are individuals diagnosed with ADHD who need a non-stimulant option.

Absolute contraindications

• Known hypersensitivity to atomoxetine or any capsule excipients.
• Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI.
• Narrow-angle glaucoma (risk of increased intra-ocular pressure).

Relative contraindications / cautions

• Severe cardiovascular disease (e.g., uncontrolled hypertension, arrhythmias).
• Hepatic impairment (dose may need adjustment).
• History of bipolar disorder or psychosis (monitor for mood changes).
• Pregnancy & lactation: Use only if potential benefit outweighs risk; animal studies show no teratogenicity, but human data are limited.

Special populations

• Pediatrics: Dosing based on weight; children <70 kg often start at 0.5 mg/kg/day.
• Elderly: Start at the lowest available dose and titrate slowly.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Decreased appetite
• Dry mouth
• Insomnia or somnolence (individual response varies)
• Nausea or abdominal discomfort
• Dizziness

These effects are usually mild to moderate and often improve with continued therapy.

Serious Adverse Events

• Suicidal thoughts: Increased risk in children, adolescents, and young adults; monitor mood closely.
• Liver injury: Rare but possible; watch for jaundice, dark urine, or abdominal pain.
• Cardiovascular events: Hypertension, tachycardia, or rare arrhythmias; assess baseline blood pressure and heart rate.
• Priapism: Persistent, painful erection; requires immediate medical attention.

Drug Interactions

• Major: Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) can raise atomoxetine levels → dose reduction recommended.
• Moderate: Drugs that affect heart rate or blood pressure (e.g., antihypertensives) may require monitoring.
• Avoid: Concurrent MAOIs; discontinue MAOI at least 14 days before starting atomoxetine.

Food and Lifestyle Interactions

• Food does not significantly alter absorption; capsules may be taken with or without meals.
• Alcohol does not affect atomoxetine pharmacokinetics but may worsen dizziness or sedation.
• Caution when operating machinery until individual response is known.

How to Take Strattera

• Standard adult dosing:
• Start with 40 mg once daily (available capsule).
• After at least 3 weeks, dose may be increased to 80 mg daily, based on response and tolerability.
• Pediatric dosing (weight-based):
• 0.5 mg/kg/day for children <70 kg (typically a 10 mg or 18 mg capsule).
• May be increased to 1.2 mg/kg/day after 3 weeks (maximum 1.4 mg/kg/day, not to exceed 100 mg).
• Administration tips:
• Swallow capsule whole; do not crush or chew.
• Take at the same time each day to maintain steady levels.
• Missed dose: Take the missed dose as soon as remembered unless it is near the time of the next scheduled dose; do not double-dose.
• Overdose: Symptoms may include vomiting, agitation, tachycardia, or seizures. Seek emergency care; activated charcoal may be considered.
• Discontinuation: No taper is required, but abrupt cessation may lead to rebound ADHD symptoms; discuss plan with prescriber.

Note: Dosing must be individualized; the ranges above reflect typical practice but are not a substitute for professional guidance.

Monitoring and Follow-Up

• Baseline assessment: Blood pressure, heart rate, height/weight, liver function tests (LFTs).
• During titration: Check blood pressure and pulse weekly for the first month, then monthly.
• Long-term: Periodic LFTs (especially in patients with hepatic risk factors) and mental-health monitoring for suicidal ideation.

Storage and Handling

• Store capsules at room temperature (15-30 °C), protected from moisture and light.
• Keep out of reach of children; use a child-proof container.
• Do not use beyond the expiry date printed on the package.

Medication-Specific Glossary

Selective Norepinephrine Reuptake Inhibitor (NRI)

A drug class that blocks the re-absorption of norepinephrine into presynaptic neurons, increasing its concentration in the synaptic cleft.

First-Pass Metabolism

The rapid uptake and metabolism of a drug by the liver after oral administration, before it reaches systemic circulation.

CYP2D6 Metabolizer Status

Genetic variation that influences how quickly an individual processes certain medications, including atomoxetine. Poor metabolizers achieve higher plasma levels.

Therapeutic Window

The dosage range in which a medication provides optimal efficacy with minimal adverse effects.

QT Interval Prolongation

An extension of the heart’s electrical repolarisation period on an ECG, which can increase the risk of arrhythmias.

Medical Disclaimer

This article provides educational information about Strattera (atomoxetine) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.